Our scientists are experienced in developing injectable, oral, and topical nanoparticles (liposomes or polymer) from 30-200 nm in size to enhance your product’s safety, efficacy, and bioavailability. We also accommodate both slow and immediate release dosages.
We will work with you to develop a process for producing consistent nanoparticles with well-defined size, encapsulation, loading efficiency and drug release profiles to complement your target product profile. Our scientists have extensive experience producing liquid and lyophilized nanoparticles, and we provide efficient technology transfer to GMP manufacturing facilities.
Key factors in the development of parenteral nanoparticles:
Size of nanoparticles
Leakability of nanoparticles
Compatible with dilutents
Nanoparticles with a size of 20 nm to 10 µ can be further encapsulated using polymeric enteric coating in aqueous conditions to prevent digestion in the stomach (low pH).
Selective drug delivery in different gastrointestinal regions.
Increased PK profile due to presence of safe permeability enhancers.
Capable of adding muco-adhesive agent to the micro particle, increasing the life span of the drug in the intestines and resulting in more bioavailability.
Expertise in oral delivery of peptides, enzymes, and proteins, including IgG.
Nanoparticles-based topical delivery systems are successfully used to treat dermatological diseases such as psoriasis, contact dermatitis, and skin cancer. Our scientists can prepare ultra-small nanoparticles (< 40 nm) that will penetrate the targeted skin strata, a demonstrably effective treatment.